


Instructions For Use

Arthrex-ABPS

Autologous Blood Processing System



Arthrex[®]
Vet Systems

Preparation of Autologous Blood Serum

Defects in articular cartilage can induce osteoarthritis by causing molecular changes in the synovial fluid. One of the major inducers of osteoarthritis is the general inflammatory cytokine Interleukin-1 (IL-1) which plays a key role in accelerating tissue destruction and the repair mechanisms.

In a healthy joint, IL-1 and Interleukin-1 receptor antagonist (IL-1Ra) are in balanced concentrations. In cases of osteoarthritis, there is not sufficient IL-1Ra produced to block the destructive effects of the increased IL-1. The result is inflammation, joint pain, and finally cartilage destruction.

The following technique explains how to process autologous serum containing increased levels of anabolic and inhibitory cytokines for use at the point of care.



Products

Arthrex-ABPS **VAR-1011**
Kit contains one Arthrex-ABPS device with dual ports, one 60 mL syringe and one butterfly cannula

Incubator **VAR-1040**

Centrifuge **ABS-10019**

Arthrex-ABPS Rotor **VAR-1021**

Technique



After routine preparation of the jugular vein, put on sterile gloves. Hook up the enclosed butterfly needle of the kit to the 60 mL syringe and use the butterfly needle to puncture the jugular vein.



Draw 50 mL of blood into the syringe. Remove the butterfly cannula from the jugular and detach from the syringe.



Remove the red tethered cap and loosen the white tethered cap on the Arthrex-ABPS device.



Attach the syringe with blood to the red luer and inject the blood into the Arthrex-ABPS device while holding the devices at about a 60° angle.



Place the incubated Arthrex-ABPS device into the centrifuge and spin at 4000 rpm for 10 minutes. The centrifuge should contain proper counter weight, if appropriate.



Detach the 60 mL syringe, recap and tighten both tethered caps and then gently rock the blood in the Arthrex-ABPS device. It is recommended that you label the Arthrex Arthrex-ABPS device with the owner, patient name, date and time.



Using aseptic technique, remove the white tethered cap from the Arthrex-ABPS device. Slowly draw the serum into a 20 mL syringe using a spinal needle. Be careful to not pull up any red blood cells.



Place the Arthrex-ABPS device horizontally, the red cap down and the white cap up, in an incubator for approximately 16-24 hours at 37° C. Do not exceed 24 hours.



Attach a sterile .22 um millipore filter and a female-female luer lock adapter between the 20 mL syringe containing the serum and an empty sterile 6 mL syringe. Transfer 4 mL of serum to the 6 mL syringe, detach the 6 mL syringe and cap. Repeat until all serum has been transferred through the sterile filter into the 6 mL syringes. Individual doses may be used immediately or frozen at -18° C for use at a later date.

Excess blood should be disposed of and disposal documented according to applicable regulations. When using at site of treatment, a sterile filter should be placed on the syringe containing the autologous serum prior to use.

References

1. M. Goldring, *Osteoarthritis and Cartilage: The Role of Cytokines*. Current Rheumatology Reports 2000; 2:459-465.
2. W. Arend, M. Malyak, C. Guthridge, C. Gabay, *Interleukin-1 Receptor Antagonist: Role in Biology*. Annual Review of Immunology 1998; 16:27-55.
3. Thomas Weinberger, Equine Clinic Burg Mueggenhausen, *Postoperative Intraarticular Treatment of Joint Disease in Horses with Autologous Enriched IL-1Ra Protein Solution - A New Biotechnical Approach*.
4. Thomas Weinberger, Equine Clinic Burg Mueggenhausen, *Intraarticular Treatment of Coffin-Joint Disease in Horses with Autologous IL-1 Enriched Protein Solution*.
5. J. Nixon, L. Haupt, D. Frisbie, S. Morisset, C. W. McIlwraith, P. Robbins, S. Ghivizzani, A. Evans, *Enhanced Cartilage Repair by Gene-Mediated Combination Insulin-Like Growth Factor-1/Interleukin-1 Receptor Antagonist Therapy*. Proc Orthop Res Soc 2002; 276.
6. D. Frisbie, G. Trotter, S. Ghivizzani, P. Robbins, C. Evans, C. W. McIlwraith, *Interleukin-1 Receptor Antagonist (IL-1Ra) Delivery Through Adenoviral Mediated Gene Transfer as a Treatment for Equine Joint Disease*. Proc Orthop Res Soc. 2000.



www.arthrexvetsystems.com

European Sales Office*:
Augustinusstr. 11c
D-50226 Frechen
Tel: +49-2234-92 85-0
Fax: +49-2234-92 85-77

Arthrex Vet Systems is a division of Arthrex® Inc., manufacturer of over 3,000 products for arthroscopic and minimally invasive orthopaedic surgical procedures. Arthrex has been a leader in arthroscopic and orthopaedic solutions for over 27 years. Investing in Arthrex products means you have chosen a company committed to uncompromising quality and constant product innovation, while providing you with the most competent technical customer support in the industry.

* Arthrex Vet Systems European Sales Office is a division of Arthrex Medizinische Instrumente GmbH, Carl-Zeiss-Str. 8, 85748 Garching, Germany.

This Product is for Veterinary Use Only